Abstracts tagged "juvenile idiopathic arthritis (JIA) and synovial cells"

Abstract Number: 380 • 2016 ACR/ARHP Annual Meeting
Linear Discriminant Analysis of Cultured Fibroblast-like Synoviocytes Identifies 6 Candidate Genes Which Predict Extended Course in Juvenile Idiopathic Arthritis
AnneMarie Brescia¹, Megan Simonds², Suzanne McCahan³, Tim Bunnell³, Kathleen E. Sullivan⁴ and Carlos D. Rosé¹, ¹Pediatric Rheumatology, Thomas Jefferson University/ AI duPont Hospital for Children, Wilmington, DE, ²Nemours, Nemours Biomedical Research, Wilmington, DE, ³Nemours Biomedical Research, Wilmington, DE, ⁴Allergy Immunology, The Children's Hospital of Philadelphia, Philadelphia, PA
Background/Purpose: The goal of this project is the identification of informative synovial biomarkers to predict which children with oligoarticular juvenile idiopathic arthritis (JIA) will have…
Abstract Number: 2467 • 2015 ACR/ARHP Annual Meeting
Interaction Between Senescent T Cells and Fibrocyte-like Cells through CD31, TNFα, and IL-17 Create a Tissue Destructive Environment in the Synovium in Juvenile Idiopathic Arthritis
Ian D. Ferguson¹, Patricia Griffin², Hiroshi Yano³, Joshua J. Michel², Jeffrey A. Dvergsten⁴, Sarah L. Gaffen⁵, Margalit E. Rosenkranz¹, Daniel A. Kietz¹ and Abbe N. Vallejo¹, ¹Department of Pediatrics, Children's Hospital of Pittsburgh, University of Pittsburgh School of Medicine, Pittsburgh, PA, ²Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, PA, ³Department of Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ⁴Department of Pediatrics, Duke University Medical Center, Durham, NC, ⁵Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, PA
Background/Purpose: T cells are considered effectors of immunopathology in JIA. In previous work, we reported dominance of senescent CD8T cells in synovial fluid of children…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].